spacer
home > ebr > winter 2018 > utmost integrity
PUBLICATIONS
European Biopharmaceutical Review

Utmost Integrity

EBR:Why is data integrity so important to the biopharmaceutical industry?

Darren Barrington-Light: The importance of data integrity is nothing new: the accuracy, consistency and completeness of biopharma data has long been of interest to regulatory bodies. However, as international outsourcing becomes increasingly commonplace and supply chains grow in complexity, regulatory authorities are raising their expectations when it comes to the integrity of this data. We have seen from a number of highprofile cases that practices that might once have passed are now inadequate from a regulatory standpoint.

Brian Alliston: At the end of the day, the products we produce must be effective and safe to use. All of us in the biopharma industry have a responsibility to patients to be up to date with the latest data integrity requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Darren Barrington-Light is a Senior Manager Product Marketing at Thermo Fisher Scientific, with over 23 years’ experience in the fields of analytical chemistry, chromatography hardware and computer software. After working with Chromeleon CDS for nearly 13 years, he joined the Chromeleon CDS product management team seven years ago, where he has been involved in all aspects of the software’s development.

Brian Alliston is a Data Integrity Expert and CDS Specialist at Sterling Pharma Solutions, where he heads the Chromeleon administration team. He supports quality control and development analysts in the use of Chromeleon CDS and oversees the development of training procedures, SOPs and product-specific report templates.

spacer
Darren Barrington-Light
spacer
spacer
spacer
Brian Alliston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement